Abstract
Dysregulated immune function in older adults is a hallmark of aging and affects the ability of this vulnerable population to resist infection and respond to vaccination. Pneumonia and influenza are the leading causes of hospitalization and death from infectious disease, and lower respiratory tract infections are the third leading cause of death worldwide (WHO, Media centre fact sheets. Available at: http://www.who.int/mediacentre/factsheets/fs310/en/index.html. Accessed 18 Mar 2018). The decline in immune function with aging is now recognized as being more than immunosenescence. Inflammatory processes associated with the immune response are critical to protection against severe infections, but tissue damage occurs when this response becomes chronic. As we grow older, our ability to regulate this response declines, which leads to the accumulation of high levels of inflammatory mediators circulating in the blood and ongoing tissue damage – this process defines “inflammaging” and appears to be fundamentally implicated in the accelerated progression of chronic diseases, functional decline, and loss of resilience with aging. This chapter will focus on vaccine preventable disability and the current recommendations for vaccination in the population age 50 and older who bear the greatest burden of multiple chronic conditions. Primary, secondary, and tertiary prevention strategies to address the challenges of pneumonia and influenza and herpes zoster start with vaccination and the basics of healthy diets, exercise, and smoking cessation in an aging population.
Keywords
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Tinetti ME, Fried TR, Boyd CM. Designing health care for the most common chronic condition--multimorbidity. JAMA. 2012;307:2493–4.
Schellevis FG. Epidemiology of multiple chronic conditions: an international perspective. J Comorb. 2013;3:36–40.
Bergman H, Ferrucci L, Guralnik J, et al. Frailty: an emerging research and clinical paradigm--issues and controversies. J Gerontol. 2007;62:731–7.
Strandberg TE, Pitkala KH. Frailty in elderly people. Lancet. 2007;369:1328–9.
Inouye SK, Studenski S, Tinetti ME, Kuchel GA. Geriatric syndromes: clinical, research, and policy implications of a core geriatric concept. J Am Geriatr Soc. 2007;55:780–91.
Bauer JM, De Castro A, Bosco N, et al. Influenza vaccine response in community-dwelling German prefrail and frail individuals. Immun Ageing. 2017;14:17.
Zhang HT, McGrath LJ, Wyss R, Ellis AR, Sturmer T. Controlling confounding by frailty when estimating influenza vaccine effectiveness using predictors of dependency in activities of daily living. Pharmacoepidemiol Drug Saf. 2017;26:1500–6.
Moehling KK, Nowalk MP, Lin CJ, et al. The effect of frailty on HAI response to influenza vaccine among community-dwelling adults >/= 50 years of age. Hum Vaccin Immunother. 2018;14(2):361–7.
Fried LP, Ferrucci L, Darer J, Williamson JD, Anderson G. Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol. 2004;59:255–63.
Stretton CM, Latham NK, Carter KN, Lee AC, Anderson CS. Determinants of physical health in frail older people: the importance of self-efficacy. Clin Rehabil. 2006;20:357–66.
Rockwood K, Rockwood MR, Mitnitski A. Physiological redundancy in older adults in relation to the change with age in the slope of a frailty index. J Am Geriatr Soc. 2010;58:318–23.
Song X, Mitnitski A, Rockwood K. Prevalence and 10-year outcomes of frailty in older adults in relation to deficit accumulation. J Am Geriatr Soc. 2010;58:681–7.
Andrew MK, Keefe JM. Social vulnerability from a social ecology perspective: a cohort study of older adults from the National Population Health Survey of Canada. BMC Geriatr. 2014;14:90.
Andrew MK, Mitnitski AB, Rockwood K. Social vulnerability, frailty and mortality in elderly people. PLoS One. 2008;3:e2232.
Andrew MK, Mitnitski A, Kirkland SA, Rockwood K. The impact of social vulnerability on the survival of the fittest older adults. Age Ageing. 2012;41:161–5.
Prior A, Fenger-Gron M, Larsen KK, et al. The association between perceived stress and mortality among people with multimorbidity: a prospective population-based cohort study. Am J Epidemiol. 2016;184:199–210.
Covinsky KE, Palmer RM, Fortinsky RH, et al. Loss of independence in activities of daily living in older adults hospitalized with medical illnesses: increased vulnerability with age. J Am Geriatr Soc. 2003;51:451–8.
Andrew MK, MacDonald S, Ye L, et al. Impact of frailty on influenza vaccine effectiveness and clinical outcomes: experience from the Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS) Network 2011/12 Season Canadian Immunization Conference. Ottawa, 2016.
McElhaney JE, Andrew MK, McNeil SA. Estimating influenza vaccine effectiveness: evolution of methods to better understand effects of confounding in older adults. Vaccine. 2017;35:6269–74.
Franceschi C, Olivieri F, Marchegiani F, et al. Genes involved in immune response/inflammation, IGF1/insulin pathway and response to oxidative stress play a major role in the genetics of human longevity: the lesson of centenarians. Mech Ageing Dev. 2005;126:351–61.
Franceschi C, Capri M, Monti D, et al. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev. 2007;128:92–105.
Staras SA, Dollard SC, Radford KW, Flanders WD, Pass RF, Cannon MJ. Seroprevalence of cytomegalovirus infection in the United States, 1988–1994. Clin Infect Dis. 2006;43:1143–51.
Derhovanessian E, Larbi A, Pawelec G. Biomarkers of human immunosenescence: impact of Cytomegalovirus infection. Curr Opin Immunol. 2009;21:440–5.
Moro-Garcia MA, Alonso-Arias R, Lopez-Vazquez A, et al. Relationship between functional ability in older people, immune system status, and intensity of response to CMV. Age (Dordrecht, Netherlands). 2012;34:479–95.
Reichert TA, Simonsen L, Sharma A, Pardo SA, Fedson DS, Miller MA. Influenza and the winter increase in mortality in the United States, 1959–1999. Am J Epidemiol. 2004;160:492–502.
Corrales-Medina VF, Suh KN, Rose G, et al. Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies. PLoS Med. 2011;8:e1001048.
Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179–86.
Glezen WP, Greenberg SB, Atmar RL, Piedra PA, Couch RB. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA. 2000;283:499–505.
Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA. 2004;292:1333–40.
Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005;352:1749–59.
Muller EA. Influence of training and of activity on muscle strength. Arch Phys Med Rehabil. 1970;51:449–62.
Harper CM, Lyles YM. Physiology and complications of bed rest. J Am Geriatr Soc. 1988;36:1047–54.
Kortebein P, Ferrando A, Lombeida J, Wolfe R, Evans WJ. Effect of 10 days of bed rest on skeletal muscle in healthy older adults. JAMA. 2007;297:1772–4.
Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med. 1994;331:778–84.
Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med. 2003;348:1322–32.
Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci. 2014;69(Suppl 1):S4–9.
Ferrucci L, Guralnik JM, Pahor M, Corti MC, Havlik RJ. Hospital diagnoses, Medicare charges, and nursing home admissions in the year when older persons become severely disabled. JAMA. 1997;277:728–34.
World Health Organization. Influenza (seasonal) fact sheet. Available at: http://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal). Accessed 9 Aug 2018.
Centers for Disease Control Weekly U.S. Influenza Surveillance Report (FluView), 2017.
Control CfD. Flu Surv-Net. Available at: https://www.cdc.gov/flu/weekly/weeklyarchives2017-2018/EIPrates49.html.
Skowronski DM, Hottes TS, McElhaney JE, et al. Immuno-epidemiologic correlates of pandemic H1N1 surveillance observations: higher antibody and lower cell-mediated immune responses with advanced age. J Infect Dis. 2011;203:158–67.
Skowronski DM, Chambers C, Sabaiduc S, et al. Pre- and postpandemic estimates of 2009 pandemic influenza A(H1N1) seroprotection to inform surveillance-based incidence, by age, during the 2013–2014 epidemic in Canada. J Infect Dis. 2015;211:109–14.
Bernstein E, Kaye D, Abrutyn E, Gross P, Dorfman M, Murasko DM. Immune response to influenza vaccination in a large healthy elderly population. Vaccine. 1999;17:82–94.
Gardner EM, Bernstein ED, Dran S, et al. Characterization of antibody responses to annual influenza vaccination over four years in a healthy elderly population. Vaccine. 2001;19:4610–7.
Murasko DM, Bernstein ED, Gardner EM, et al. Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. Exp Gerontol. 2002;37:427–39.
Effros RB. Role of T lymphocyte replicative senescence in vaccine efficacy. Vaccine. 2007;25:599–604.
McElhaney JE, Effros RB. Immunosenescence: what does it mean to health outcomes in older adults? Curr Opin Immunol. 2009;21:418–24.
McElhaney JE. Prevention of infectious diseases in older adults through immunization: the challenge of the senescent immune response. Expert Rev Vaccines. 2009;8:593–606.
DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371:635–45.
Merani S, Kuchel GA, Kleppinger A, McElhaney JE. Influenza vaccine-mediated protection in older adults: Impact of influenza infection, cytomegalovirus serostatus and vaccine dosage. Exp Gerontol. 2018;107:116–25.
Gravenstein S, Davidson HE, Taljaard M, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccination on numbers of US nursing home residents admitted to hospital: a cluster-randomised trial. Lancet Respir Med. 2017;5:738–46.
Raviotta JM, Smith KJ, DePasse J, et al. Cost-effectiveness and public health effect of influenza vaccine strategies for U.S. elderly adults. J Am Geriatr Soc. 2016;64:2126–31.
Mullooly JP, Bridges CB, Thompson WW, et al. Influenza- and RSV-associated hospitalizations among adults. Vaccine. 2007;25:846–55.
Falsey AR, McElhaney JE, Beran J, et al. Respiratory syncytial virus and other respiratory viral infections in older adults with moderate to severe influenza-like illness. J Infect Dis. 2014;209:1873–81.
Falsey AR, Treanor JJ, Betts RF, Walsh EE. Viral respiratory infections in the institutionalized elderly: clinical and epidemiologic findings. J Am Geriatr Soc. 1992;40:115–9.
WHO. Media centre fact sheets. Available at: http://www.who.int/mediacentre/factsheets/fs310/en/index.html. Accessed 18 Mar 2018.
Corrales-Medina VF, Musher DM, Wells GA, Chirinos JA, Chen L, Fine MJ. Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation. 2012;125:773–81.
Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–128.
Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67:71–9.
Lode HM. Managing community-acquired pneumonia: a European perspective. Respir Med. 2007;101:1864–73.
Fedson DS. Clinical practice and public policy for influenza and pneumococcal vaccination of the elderly. Clin Geriatr Med. 1992;8:183–99.
Sisk JE, Moskowitz AJ, Whang W, et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA. 1997;278:1333–9.
Rubins JB, Alter M, Loch J, Janoff EN. Determination of antibody responses of elderly adults to all 23 capsular polysaccharides after pneumococcal vaccination. Infect Immun. 1999;67:5979–84.
Kolibab K, Smithson SL, Shriner AK, et al. Immune response to pneumococcal polysaccharides 4 and 14 in elderly and young adults. I. Antibody concentrations, avidity and functional activity. Immun Ageing. 2005;2:10.
Lamontagne F, Garant MP, Carvalho JC, Lanthier L, Smieja M, Pilon D. Pneumococcal vaccination and risk of myocardial infarction. CMAJ. 2008;179:773–7.
Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372:1114–25.
Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med. 1965;58:9–20.
Schmader K. Herpes zoster in older adults. Clin Infect Dis. 2001;32:1481–6. Epub 2001 Apr 17.
Brisson M, Edmunds WJ, Law B, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect. 2001;127:305–14.
Oxman MN, Levin MJ. Vaccination against herpes zoster and postherpetic neuralgia. J Infect Dis. 2008;197(Suppl 2):S228–36.
Drolet M, Brisson M, Schmader KE, et al. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ. 2010;182:1731–6.
Cunningham AL, Dworkin RH. The management of post-herpetic neuralgia. BMJ. 2000;321:778–9.
Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis. 2004;4:26–33.
Arvin AM, Moffat JF, Redman R. Varicella-zoster virus: aspects of pathogenesis and host response to natural infection and varicella vaccine. Adv Virus Res. 1996;46:263–309.
Baiker A, Fabel K, Cozzio A, et al. Varicella-zoster virus infection of human neural cells in vivo. Proc Natl Acad Sci U S A. 2004;101:10792–7.
Vukmanovic-Stejic M, Sandhu D, Sobande TO, et al. Varicella zoster-specific CD4+Foxp3+ T cells accumulate after cutaneous antigen challenge in humans. J Immunol. 2013;190:977–86.
Vukmanovic-Stejic M, Sandhu D, Seidel JA, et al. The characterization of varicella zoster virus-specific T cells in skin and blood during aging. J Invest Dermatol. 2015;135:1752–62.
Arvin AM. Humoral and cellular immunity to varicella-zoster virus: an overview. J Infect Dis. 2008;197(Suppl 2):S58–60.
Steain M, Sutherland JP, Rodriguez M, Cunningham AL, Slobedman B, Abendroth A. Analysis of T cell responses during active varicella-zoster virus reactivation in human ganglia. J Virol. 2014;88:2704–16.
Gowrishankar K, Steain M, Cunningham AL, et al. Characterization of the host immune response in human Ganglia after herpes zoster. J Virol. 2010;84:8861–70.
Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271–84.
Sei JJ, Cox KS, Dubey SA, et al. Effector and central memory poly-functional CD4(+) and CD8(+) T cells are boosted upon ZOSTAVAX((R)) vaccination. Front Immunol. 2015;6:553.
Cunningham AL, Heineman TC, Lal H, et al. Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged >/=50 years. J Infect Dis. 2018;217:1750.
Didierlaurent AM, Collignon C, Bourguignon P, et al. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells. J Immunol. 2014;193:1920–30.
Cunningham AL. The herpes zoster subunit vaccine. Expert Opin Biol Ther. 2016;16:265–71.
Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372:2087–96.
Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375:1019–32.
Evans CT, Johnson S. Prevention of Clostridium difficile infection with probiotics. Clin Infect Dis. 2015;60(Suppl 2):S122–8.
Shen NT, Maw A, Tmanova LL, et al. Timely use of probiotics in hospitalized adults prevents Clostridium difficile infection: a systematic review with meta-regression analysis. Gastroenterology. 2017;152:1889–900 e9.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
McElhaney, J.E., Andrew, M.K., McNeil, S., Kuchel, G.A. (2019). Preventing Infections and Healthy Aging. In: Coll, P. (eds) Healthy Aging. Springer, Cham. https://doi.org/10.1007/978-3-030-06200-2_16
Download citation
DOI: https://doi.org/10.1007/978-3-030-06200-2_16
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-06199-9
Online ISBN: 978-3-030-06200-2
eBook Packages: MedicineMedicine (R0)